ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL)

Objective: to analyze the results of tofacitinib (TOFA) therapy in real clinical practice according to the All-Russian Arthritis Registry (OREL).
Subjects and methods. The OREL Registry included 347 patients (286 (82%) women and 61 (18%) men) with rheumatoid arthritis (RA) who initiated TOFA therapy. The male:female ratio was 1:4.7. The patients’ median age at onset of the disease was 42 years; its duration was 8 years. Most of the patients included in the registry had extended- (n=171 (52%)) or late- (n=148 (45%)) stage of RA.
Results and discussion. Prior to initiation of TOFA therapy, RA activity according to DAS28 was high and moderate in 91 (64.5%) and 40 (28.4%) patients, respectively; the median DAS28 value was 5.5 [4.6; 6.2]; SDAI – 30.5 [21.4; 42.9], and CDAI – 28.2 [20.0; 37.1]. The use of TOFA was accompanied by significant decrease of disease activity. After 12 weeks, high RA activity was persistent in 32 (22.7%) patients; the number of patients with moderate activity increased to 77 (54.6%), that of those with low activity rose to 15 (10.6%); remission was observed in 17 (12.1%) patients. 216 (62.6%) and 76 (22%) patients received TOFA as first- and second-line therapy, respectively. TOFA was most frequently prescribed when tumor necrosis factor-á inhibitors (19.6%), rituximab (7.8%), tocilizumab (4.3%), and abatacept (5.2%) were insufficiently effective or poorly tolerated.
Conclusion. The results of using TOFA in real clinical practice may suggest that the drug has high efficacy in patients with RA. TOFA can be used at a dose of 5 or 10 mg twice daily as both alone and in combination with disease-modifying anti-rheumatic drugs. TOFA showed similar efficacy in patients who had earlier taken biological agents and in those who had not.

1. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi: 10.1038/nrdp.2018.1

2. Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 549 с. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biologicals in the treatment of rheumatoid arthritis.]. Moscow: IMA-PRESS; 2013. 549 p. (In Russ.)].

3. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276-89. doi: 10.1038/nrrheum.2015.8

4. Smolen JS, Aletaha D, McInnes I. Rheumatoid arthritis. Lancet. 2016;388:2023-38. doi: 10.1016/S0140-6736(16)30173-8

5. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/nrd.2017.201

6. Hammaren HM, Virtanen AT, Raivola J, Silvennoinen O. The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2018 Apr 20. doi: 10.1016/j.cyto.2018.03.041

7. Gadina M, Johnson C, Schwartz D, et al. Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol. 2018;104(3):499-514. doi: 10.1002/JLB.5RI0218-084R

8. Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16 [Nasonov EL, Lila AM. Janus kinase inhibitors in immunoinflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16 (In Russ.)].

9. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77. doi: 10.1136/annrheumdis-2016-210715

10. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheum. 2016;68(1):1-26. doi: 10.1002/art.39480

11. Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2020. 448 с. [Nasonov EL, editor. Revmatologiya. Rossiiskie klinicheskie rekomendatsii [Rheumatology. Russian clinical guidelines]. Moscow: GEOTAR-Media; 2020. 448 p. (In Russ.)].

12. Dhillon S. Tofacitinib: A review in rheumatoid arthritis. Drugs. 2017 Dec;77(18):1987-2001. doi: 10.1007/s40265-017-0835-9

13. Charles-Schoeman C, Burmester G, Nash P, et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016;75(7):1293-301. doi: 10.1136/annrheumdis2014-207178

14. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234-43. doi: 10.1038/nrrheum.2017.23

15. Насонов ЕЛ, Авдеева АС, Лила АМ. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть I). Научно-практическая ревматология. 2020;58(1):62-79. doi: 10.14412/1995-4484-2020-62-79 [Nasonov EL, Avdeeva AS, Lila AM. Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2020;58(1):62-79. doi: 10.14412/1995-4484-2020-62-79 (In Russ.)].

16. Fleischmann R, Mysler E, Hall S, et al; ORAL Strategy Investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with MTX, and adalimumab with MTX in patients with rheumatoid arthritis (ORAL Strategy): a phase IIIb/IV, doubleblind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457-68. doi: 10.1016/S0140-6736(17)31618-5

17. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus MTX in rheumatoid arthritis. N Engl J Med. 2014;370:2377-86. doi: 10.1056/NEJMoa1310476

18. Tanaka Y, Suzuki M, Nakamura H, et al. Tofacitinib Study Investigators. Phase II study of tofacitinib (CP-690,550) combined with MTX in patients with rheumatoid arthritis and an inadequate response to MTX. Arthritis Care Res (Hoboken). 2011;63:1150-8. doi: 10.1002/acr.20494

19. Tanaka Y, Takeuchi T, Yamanaka H, et al. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, Phase 2 study. Mod Rheumatol. 2015;25:514-21. doi: 10.3109/14397595.2014.995875

20. Van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving MTX twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559-70. doi: 10.1002/art.37816

21. Van der Heijde D, Strand V, Tanaka Y, et al. ORAL Scan Investigators. Tofacitinib in combination with Methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study. Arthritis Rheum. 2019;71(6):878-91. doi: 10.1002/art.40803

22. Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253-61. doi: 10.7326/0003-4819-159-4-201308200-00006

23. Насонов ЕЛ, Каратеев ДЕ, Сатыбалдыев АМ и др. Ревматоидный артрит в Российской Федерации по данным Российского регистра больных артритом (сообщение I). Научно-практическая ревматология. 2015;53(5):472-84. doi: 10.14412/1995-4484-2015-472-484 [Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to Russian Arthritis Registry data (Communication 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(5):472- 84. doi: 10.14412/1995-4484-2015-472-484 (In Russ.)].

24. Bird P, Littlejohn G, Butcher B, et al. Evaluation of effectiveness and usage patterns of Tofacitinib in treatment of rheumatoid arthritis in Australia: An analysis from the OPAL-QUMI Real World Dataset [abstract]. Arthritis Rheum. 2019;71 Suppl. 10. doi: 10.1136/annrheumdis-2019-eular.5216

25. Reed GW, Gerber RA, Shan Y, et al. Real-world comparative effectiveness of Tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis. Rheumatol Ther. 2019 Nov 9. doi: 10.1007/s40744-019-00177-4

26. Kavanaugh A, Reed GW, Saunders KC, et al. Clinical characteristics of RA patients newly prescribed tofacitinib citrate (tofacitinib) in the United States after food and drug administration approval: results from the CORRONA US rheumatoid arthritis registry. Ann Rheum Dis. 2015;74:1041. doi: 10.1136/annrheumdis-2015-eular.1760

27. Kavanaugh AF, Geier J, Bingham CI, et al. Real world results from a post-approval safety surveillance of tofacitinib (Xeljanz): Over 3 year results from an ongoing US-based rheumatoid arthritis registry. Arthritis Rheum. 2016;68(S10):Abstract 2595.

28. Harnett J, Gerber R, Gruben D, et al. Evaluation of real-world ex perience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: Data from a U.S. Administrative Claims Database. J Manag Care Spec Pharm. 2016;22:1457-71. doi: 10.18553/jmcp.2016.22.12.1457

29. Smith T, Harnett J, Gruben D, et al. Real-world ex perience with tofacitinib versus adalimumab and etanercept in biologic-naive patients with RA previously treated with methotrexate: Data from a US Administrative Health- care Insurance Claims Database. Arthritis Rheum. 2017;69(S10):Abstract 2831.

30. Mori S, Yoshitama T, Ueki Y. Tofacitinib therapy for rheumatoid arthritis: A direct comparison study between biologic-naive and experienced patients. Intern Med. 2018;57:663-70. doi: 10.2169/internalmedicine.9341-17

31. Finckh A, Herzog L, Scherer A. Drug retention of tofacitinib versus biologic antirheumatic agents in rheumatoid arthritis: observational data from the Swiss SCQM registry. Ann Rheum Dis. 2017;76 Suppl.2):267. doi: 10.1136/annrheumdis-2017-eular.6804

32. Iwamoto N, Tsuji S, Tanakatani A, et al. Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PLoS One. 2017;12:e0177057. doi: 10.1371/journal.pone.0177057